Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mydecine Innovations Group Inc (OP: MYCOF )

0.0039 +0.0001 (+2.63%)
Streaming Delayed Price Updated: 12:13 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mydecine Innovations Group Inc

< Previous 1 2 3 4 5 6 7 Next >
Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval
Psychedelics and mycology company Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Which Psychedelic Stock ETF Is Right For You?
This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes. 
Via Talk Markets
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Last Week In Psychedelics: 
Via Benzinga
Cannabis And Psychedelic Drug Stock Performances Were Mixed Last Week
The performance of the psychedelic-focused index components substantially outshone the weed stocks. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
National Suicide Prevention Week Shines Light on Psychedelic Treatments
Via FinancialNewsMedia
Psychedelic Drug Industry Report Card For 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
Magic Mushroom Drug Stock Performances YTD
Of the 35 companies involved in clinical stage research of psychedelic substances, 20 are researching the benefits of psilocybin, the primary psychoactive ingredient in “magic mushrooms”. 
Via Talk Markets
PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
On Wednesday, PharmaDrug Inc. (CSE:PHRX) (OTC: 
Via Benzinga
Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
Beckley Psytech Closes $80 Million Series B Beckley Psytech announced 
Via Benzinga
Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation
Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) has signe... 
Via Benzinga
Which Psychedelic Drug Stock Category Outperformed Last Week
Which has performed best YTD, the Pure-Play Marijuana Drug Stocks Index or the Pure-Play Psychedelic Compounds-Based Drug Stocks Index? 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Which Psychedelic Drug Has The Most Commercial Potential?
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. 
Via Talk Markets
Marijuana Vs. Mushroom Psychedelic Drug Stocks: A Current & YTD Performance Comparison
We identify the performance of the top 8 clinical-stage psychedelic companies in each of the marijuana and mushroom drug stock categories during the past 5 trading days, July to date, and YTD. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Telehealth Boom Is Driving this Mental Health Company’s Progress
Via FinancialNewsMedia
How The Pot And Psychedelic Stocks Performed Last Week And YTD
Approximately 100 clinical-stage marijuana and mushroom/ketamine psychedelic drug stocks now trade on the various North American stock exchanges. 
Via Talk Markets
Topics Cannabis
Exposures Cannabis
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
Via Benzinga
The 6 Leading Psychedelic Stocks In Drug R&D
Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... 
Via Talk Markets
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Mydecine Identifies 4 Psychedelic-Related Drugs to Tackle the Mental Health Crisis
Photo by Christopher Ott on 
Via Benzinga
Mydecine Innovations Group Launches AI-Assisted Drug Discovery Program
Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF), a biotech company in the ... 
Via Benzinga
Psychedelic Drug Stocks Index -21% In May; Now -25% YTD
46 psychedelic drug stocks now trade on the various North American stock exchanges and the 11 with the largest market capitalizations make up the Pure-Play Psychedelic Drug Stocks Index. 
Via Talk Markets
Psyched: Nasdaq Gets Its Third Psychedelics Company, Mynd Goes Public, Delic Buys New Research Facility
The Nasdaq welcomed its third psychedelics company this week, with 
Via Benzinga
Mydecine Reports First Quarter 2021 Financial Results and Provides Business Update
Via Get News
Mydecine To Spin-Out Its U.S. Cannabis Assets By Mid July
Psychedelics and mycology company, Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Next Psychedelic Stock To Uplist On The Nasdaq?
As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next? 
Via Talk Markets
Mydecine Posts $26.9M Net Loss For 2020: What's Ahead For Psychedelic Stock
Denver-based Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.